Inspirion Wealth Advisors LLC Decreases Stock Position in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT)

Inspirion Wealth Advisors LLC decreased its stake in shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) by 45.5% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 19,964 shares of the company’s stock after selling 16,670 shares during the quarter. Inspirion Wealth Advisors LLC’s holdings in Phathom Pharmaceuticals were worth $162,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. Huntington National Bank lifted its holdings in Phathom Pharmaceuticals by 62.2% during the 3rd quarter. Huntington National Bank now owns 1,471 shares of the company’s stock worth $27,000 after buying an additional 564 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its stake in Phathom Pharmaceuticals by 41.3% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,470 shares of the company’s stock worth $43,000 after purchasing an additional 722 shares during the last quarter. US Bancorp DE boosted its holdings in Phathom Pharmaceuticals by 28.6% in the third quarter. US Bancorp DE now owns 5,248 shares of the company’s stock valued at $95,000 after purchasing an additional 1,166 shares in the last quarter. The Manufacturers Life Insurance Company boosted its holdings in Phathom Pharmaceuticals by 10.6% in the second quarter. The Manufacturers Life Insurance Company now owns 13,941 shares of the company’s stock valued at $144,000 after purchasing an additional 1,339 shares in the last quarter. Finally, Quest Partners LLC acquired a new position in shares of Phathom Pharmaceuticals in the 3rd quarter valued at $197,000. Institutional investors and hedge funds own 99.01% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on PHAT shares. HC Wainwright reissued a “buy” rating and issued a $28.00 price target on shares of Phathom Pharmaceuticals in a research report on Thursday, December 12th. Needham & Company LLC reissued a “buy” rating and issued a $28.00 target price on shares of Phathom Pharmaceuticals in a report on Friday, January 10th.

Insiders Place Their Bets

In other Phathom Pharmaceuticals news, Director Frank Karbe bought 12,500 shares of Phathom Pharmaceuticals stock in a transaction dated Friday, December 13th. The stock was acquired at an average cost of $7.93 per share, with a total value of $99,125.00. Following the completion of the acquisition, the director now owns 57,000 shares of the company’s stock, valued at approximately $452,010. This represents a 28.09 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 24.10% of the stock is currently owned by insiders.

Phathom Pharmaceuticals Stock Down 2.4 %

Shares of Phathom Pharmaceuticals stock opened at $6.96 on Friday. The firm’s fifty day simple moving average is $8.74 and its 200-day simple moving average is $12.65. Phathom Pharmaceuticals, Inc. has a 12 month low of $6.07 and a 12 month high of $19.71.

Phathom Pharmaceuticals Profile

Phathom Pharmaceuticals, Inc, biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.